Christian E.O. Roesky, PhD

Chief Executive Officer & Chairman Board of Directors
Dermaliq Therapeutics Inc.

Biography

Dr. Roesky is an executive scientist and joined Dermaliq Therapeutics Inc. in 2025 as Chief Executive Officer and Chairman of the Company’s Board of Directors. He serves on the Board since inception of the company in 2022.

With over two decades of industry experience, Dr Roesky is a proven healthcare and biotech leader with expertise in organizational strategy, global regulatory & drug development, and commercial execution.

Prior to joining Dermaliq, he was CEO Novaliq, where he successfully developed the revolutionary new drug category of water-free ocular therapies and scaled the company for its next stage of growth. Before joining Novaliq in 2016, Dr. Roesky served as General Manager for Bausch + Lomb in Europe and Commercial Director Central Europe for Abbott Diagnostics Division. Earlier in his career, he spent more about 15 years at Alcon/Novartis in varies international roles and responsibilities including General Manager Germany & Austria and Marketing Manager EURMEA.

Dr Roesky has experience across a broad range of therapeutics areas and has been directly involved with over 10 regulatory approvals in the USA, Europe and China, as well as more than 20 different licensing and financing transactions in the last 8 years.

He studied chemistry in Bonn and Freiberg (Germany) and was awarded his Ph.D. with honors from the Technical University of Freiberg.

Dr. Roesky serves as a board director at Betaliq Inc and vice chairman and board member of the BPI, the trade organization of the German pharmaceutical industry.